Fueling Life
Episode 4: Analyzing TSC’s Impact on Carbon Monoxide Diffusion Through the Lungs 150 150 Diffusion Pharmaceuticals Inc.

Episode 4: Analyzing TSC’s Impact on Carbon Monoxide Diffusion Through the Lungs

Diffusion’s Chief Medical Officer Dr. Chris Galloway provides an overview of the ILD-DLCO Trial, the third in a trio of Oxygenation Trials that will inform late-phase programs and clinical indications for lead drug candidate TSC.

Episode 3: Evaluating the Effects of TSC on Maximal Oxygen Consumption 150 150 Diffusion Pharmaceuticals Inc.

Episode 3: Evaluating the Effects of TSC on Maximal Oxygen Consumption

Chief Medical Officer Dr. Chris Galloway previews Diffusion’s Altitude Trial, the second in a trio of Oxygenation Trials that will collectively inform late phase programs and the clinical development plan for lead drug candidate TSC.

Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen 150 150 Diffusion Pharmaceuticals Inc.

Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen

Dr. Chris Galloway, Chief Medical Officer of Diffusion, explains the TCOM Trial design, top-line results, and the relevancy of this first of three Oxygenation Trials that together will inform late-phase programs and clinical indications for lead drug candidate TSC.

Episode 1: The Science of Solving for Hypoxia 150 150 Diffusion Pharmaceuticals Inc.

Episode 1: The Science of Solving for Hypoxia

Diffusion Pharmaceuticals CEO Robert Cobuzzi, Jr., PhD discusses cellular oxygen deficiency, the TSC development plan, and potential future applications for this small molecule therapeutic with a novel MOA.

Introducing Fueling Life: a Podcast from Diffusion Pharmaceuticals 150 150 Diffusion Pharmaceuticals Inc.

Introducing Fueling Life: a Podcast from Diffusion Pharmaceuticals

This podcast will discuss hypoxia, a potentially fatal shortage of oxygen in a body tissue, and cover the development plan for lead product candidate TSC, which enhances oxygen diffusion to hypoxic tissue.

Back to top